Clinical Trial

Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.

Study acronym: P versicolor
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 12, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Pityriasis versicolor is a common superficial fungal infection caused by Malassezia species, characterized by hypo- or hyper-pigmented scaly patches on the skin. Topical antifungal agents are the mainstay of treatment. Ketoconazole has been widely used; however, newer agents such as luliconazole may offer improved efficacy and shorter treatment duration. This randomized controlled study aims to compare the efficacy and safety of topical luliconazole versus topical ketoconazole in patients with pityriasis versicolor. Treatment response will be assessed clinically and mycologically to determine comparative outcomes.
Trial Details
NCT Number NCT07333170
Lead Sponsor PAEC General Hospital, Islamabad
Collaborators: PAEC general hospital
Conditions Pityriasis Versicolor
Enrollment 86 participants
Start Date 2026-02
Primary Completion 2026-07 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-01-12